Univ. Limoges, CNRS, ENSCI, SPCTS, UMR 7315, F-87000 Limoges, France.
Univ. Limoges, CNRS, ENSCI, SPCTS, UMR 7315, F-87000 Limoges, France.
J Control Release. 2017 Apr 28;252:1-17. doi: 10.1016/j.jconrel.2017.02.012. Epub 2017 Feb 21.
Effective treatment of critical-size defects is a key challenge in restorative surgery of bone. The strategy covers the implantation of biocompatible, osteoconductive, bioactive and biodegradable devices which (1) well interact with native tissue, mimic multi-dimensional and hierarchical structure of bone and (2) are able to enhance bone repair, treating post implantation pathologies or bone diseases by local delivery of therapeutic agents. Among different options, calcium phosphate biomaterials are found to be attractive choices, due to their excellent biocompatibility, customisable bioactivity and biodegradability. Several approaches have been established to enhance this material ability to be loaded with a therapeutic agent, in order to obtain an in situ controlled release that meets the clinical needs. This article reviews the most important factors influencing on both drug loading and release capacity of porous calcium phosphate bone substitutes. Characteristics of the carrier, drug/carrier interactions, experimental conditions of drug loading and evaluation of drug delivery are considered successively.
有效治疗临界尺寸缺陷是骨修复手术的关键挑战。该策略包括植入生物相容性、骨传导性、生物活性和可生物降解的装置,这些装置(1)与天然组织很好地相互作用,模拟骨的多维和层次结构,(2)能够通过局部输送治疗剂来增强骨修复,治疗植入后的病理或骨疾病。在不同的选择中,磷酸钙生物材料由于其优异的生物相容性、可定制的生物活性和可生物降解性而被认为是有吸引力的选择。已经建立了几种方法来增强这种材料加载治疗剂的能力,以获得满足临床需求的原位控制释放。本文综述了影响多孔磷酸钙骨替代物药物负载和释放能力的最重要因素。依次考虑了载体的特性、药物/载体相互作用、药物负载的实验条件和药物输送的评估。